Background: Transgenic mice bearing a murine immunoglobulin enhancer/c-myc fusion transgene (Ep,-myc) provide a useful model for Burkitt's lymphoma. Materials and Methods: Groups of 12 E,t-myc mice were treated prophylactically for 6 weeks after weaning with anti-c-myc DNA phosphorothioate (20 mg/kg/day), scrambled control DNA, or saline, delivered by micro-
INTRODUCTION
Burkitt's lymphoma constitutes the most frequent hematological malignancy of childhood (1) . Lymphoma is also a frequent result of human immunodeficiency virus (HIV) infection (1) . This malignancy, like all others, results from a multistep process of oncogene activation or suppressor gene inactivation (2) . In Burkitt's lymphoma, virtually all cases display translocation of chromosomes 8 and 14, placing the c-myc proto-oncogene from chromosome 8 under the transcriptional control of the immunoglobulin M heavy chain enhancer from chromosome 14 (3) .
To provide an animal model for childhood Burkitt's lymphoma, transgenic mice were created (4) bearing a murine immunoglobulin M enhancer/c-myc fusion transgene (E,u-myc) isolated from a mouse plasmacytoma (5) . Mice in these lines, including the Tg(IgH,Myc)BrilS7 line studied here, develop aggressive multifocal lymphoma/leukemia (4) . Tumors are prominent in 95% of such mice by 16 weeks after birth. It appears that elevated constitutive expression of c-myc mRNA and antigen does not directly induce tumor onset, but establishes a subpopulation of rapidly proliferating, immature B cells which may be transformed into a malignant phenotype by a subsequent oncogene activation (6) . These transgenic mice provide a well-characterized animal model for studying the role of c-myc activation in B cell lymphoma.
In mammalian cells, the c-myc oncogene has proved to be a reliable target for antisense DNA inhibition of gene expression (Refs. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] and Y. Shi et al., submitted). The ability of antisense DNA to turn off individual genes at will in growing cells provides a powerful tool for elucidating the role of a particular gene, and for therapeutic 648 Molecular Medicine, Volume 1, Number 6, September 1995 intervention when that gene is overexpressed or mutated. Antisense DNAs have been applied against a wide variety of target genes, in viral, bacterial, plant, and animal systems, both in whole cells (22) and in animal models (23) . It was therefore of interest to determine whether or not antisense DNA therapy could down-regulate c-myc gene expression in an animal model (24) . Nuclease-resistant methylphosphonate DNAs were administered to the E,u-myc transgenic mice by tail vein injection, distributed rapidly to the tissues, and showed no sign of degradation. This single treatment, at about 50 mg/kg, significantly decreased MYC p65 expression, measured 3-4 hr after administration (24) . Injection of a scrambled sequence, or saline, had no effect. Similarly, inhibition of restenosis has been reported in pigs by a single administration of anti-c-myc DNA phosphorothioates (25) . Furthermore, we have observed significant inhibition of tumorigenesis in nude mice by c-Ha-rastransformed cells as a result of pretreatment of the cells with anti-c-Ha-ras DNA (26) .
Having seen a decrease in MYC antigen in response to a single administration of anti-c-myc DNA methylphosphonate (24) we hypothesized that prolonged treatment of E,u-myc transgenic mice with anti-c-myc DNA, inhibiting c-myc expression in the target B cells, might preclude overproliferation of these cells, and interdict tumor progression. To test this hypothesis, DNA was administered by micro-osmotic pumps (27) to E,-myc mice which were treated continuously for 6 weeks after weaning with DNA phosphorothioates. Mice treated with saline or the scrambled control DNA displayed palpable tumors over the usual time course, but 11 of the 12 mice treated with anti-c-myc DNA were free of tumors at the age of 9 weeks, when antisense therapy ended. Surprisingly, 75% of the mice treated with antisense DNA were still free of tumors at the age of 26 weeks, implying the establishment of long-term resistance to myc-induced lymphoma.
MATERIALS AND METHODS
Transgenic Mice E,u-myc transgenic mice embryos (4) were the kind gift of Dr. Ralph Brinster. They were rinsed twice over a 24-hr period to dislodge any adherent virions and were implanted in the uteri of pseudopregnant (C57BL/6J X SJL/J)F1 hybrid female foster mothers under viral-pathogen-free conditions. The heterozygous offspring were screened for presence of a (FX174 marker sequence in the transgene by PCR amplification (28) of DNA from toe cells at birth. The reliability of this routine screening method was confirmed by Southern blot, using the c-myc probe pRyc7.4, the kind gift of Dr. Maria Luisa Veronese (29) . The mouse line is maintained by continually backcrossing E,u-myc positive males with (C57BL/6J X SJL/J)Fl hybrid females; the offspring in each generation are screened by PCR as above. This investigation was carried out in a pathogen-free animal facility accredited by AAAALAC, and was reviewed and monitored by the Institutional Animal Care and Use Committee to make sure that National Institutes of Health guidelines were followed.
Oligodeoxynucleotide Synthesis
The PCR primers 5'-dGCAACTTCGGGATGAA AATG-3' (forward) and 5'-dCGAAGCGCGCAT AAATTT-3' (reverse) were synthesized as phosphodiesters (30) on an Applied Biosystems 394 DNA synthesizer. The anti-c-myc sequence 5'-dCACGTTGAGGGGCAT-3', and the scrambled sequence 5'-dCTGCTGAGAGTCGAG-3', were synthesized as phosphorothioates (31) at a scale of 120 and 200 ,umol, on a Biosearch 8800 DNA synthesizer. Deprotected oligomers were purified by duplicate precipitation with n-butanol (32), then analyzed to verify purity by high-performance liquid chromatography (8), nuclear magnetic resonance spectroscopy (31) , and matrix-assisted laser desorption/ionization mass spectroscopy (33) . Oligomers were sterilized by passage through sterile 0.2-,um pore syringe filter units.
Micropump Administration
Groups of 12 (Fig. 2) . One of the three tumors in the antisense group was already palpable 2 weeks after the beginning of the 6 weeks of therapy; perhaps that tumor had already initiated prior to therapy. The second was detected at 15 weeks and the third at 17 weeks. The tumor-free mice treated with antisense DNA were observed up until sacrifice at 48 weeks.
An overall analysis of variance of the tumor data using the nonparametric Kruskal-Wallis procedure (38) mice prior to tumor onset, but prominent bands remained in splenic lymphocytes of tumor-bearing mice treated with saline or scrambled DNA (Fig. 3) , and in the lymphoid tumors of mice from all treatment groups (Fig. 4) . c-Myc mRNA measured in the same animals, however, was not significantly reduced either in splenic lymphocytes of the mice with the antisense treatment (Fig. 5 ) or in lymphoid tumors as compared with control groups (Fig. 6) there were no significant differences detected among the three groups in major physiological values such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine, blood urea nitrogen, glucose and blood sodium, indicating the lack of acute toxicity of phosphorothioate DNA at the therapeutic dose (Table 1) . Splenomegaly has also been reported in mice as a result of phosphorothioate DNA administration (40) . This phenomenon was also observed in the E,-myc mice treated with antisense or scrambled phosphorothioate DNAs. At an age of [12] [13] [14] [15] [16] weeks, the mass of spleens from normal mice averaged 0.1 g, while those from E,u-myc mice receiving phosphorothioates averaged 0.3 g. However, the spleens of E,u-myc mice treated with the placebo averaged 0.25 g, so that the observed splenomegaly may arise from the stress of bearing tumors and implantation of pellets or micropumps.
Procreation is usually inadvisable during chemotherapy, but three female mice treated with scrambled DNA were mated inadvertently during treatment and gave birth to normal size healthy litters. A male mouse treated with antisense DNA was mated 2 weeks after the end of therapy, and fathered two normal size healthy litters. Hence, there was no apparent acute toxicity to the gonads as a result of phosphorothioate therapy at the therapeutic dose.
DISCUSSION
When antisense DNA administration by pellet was attempted after tumor onset, autopsies revealed numerous tumors in each of the E,u-myc mice, disseminated to most of the lymph nodes, in varying sizes up to several grams. Disease progression was not halted in mice treated by pellet with antisense DNA phosphorothioates or methylphosphonates after tumor establishment. However, the lack of measurable regression may only reflect the pellet mode of administration utilized in the first two trials. Pellet administration was discarded following these unpromising results. Inconsistent, poor delivery of antisense DNA may have resulted in a low effective dose, obscuring any antisense effects. Therefore, another hypothesis to be tested holds that continuous administration of antisense DNA over many weeks might be sufficient to reduce the growth of an established tumor. However, it is apparent from Fig. 3 that one week of such therapy failed to depress MYC antigen.
One may then hypothesize that inhibition of c-myc overexpression early in life, prior to secondary neoplastic transformation, might interdict tumor formation. To test this hypothesis, antisense DNA therapy was then initiated at weaning, three weeks of age, the earliest time at which pups could be handled without danger of maternal rejection.
Subcutaneous administration was tested, and none of the mice receiving antisense DNA displayed tumors at the age of 8 weeks, when the 5 weeks of therapy ended. However, the senescence of the skin around the site of injection, in the case of antisense DNA, presented an undesirable side effect. Normally, mature epidermis includes a differentiating compartment and a proliferating compartment. MYC protein is one of the crucial factors regulating keratinocyte growth, differentiation, and apoptosis in the mature epidermis (41) . Down-regulation of c-myc expression directly induces terminal differentiation of keratinocytes, and potently initiates apoptosis, as well as inhibiting proliferation. Both lead to keratinocyte cell death. Furthermore, keratinocytes efficiently internalize oligodeoxynucleotides (42) . Therefore, we think that the dermal toxicity that occurred in the antisense-treated group was a direct effect of a high local concentration of anti-c-myc DNA.
The subcutaneous trial implied that prolonged and frequent administration of antisense DNA under the skin by syringe would be too toxic to use in a longer, larger trial. Prolonged and frequent intraperitoneal administration seemed too traumatic. Envisioning 6 weeks of therapy, we therefore decided to try antisense DNA therapy by implantation of a series of three 14-day micro-osmotic pumps. Following 1 week of such therapy, MYC antigen was suppressed in the spleens of tumor-bearing mice treated with antisense DNA (Fig. 3) , although no significant inhibition was observed in the corresponding lymphoid tumors from the same animals (Fig. 4) . Poor penetration by antisense DNA into the tumors from the blood may be one possible explanation for the lack of MYC ablation in the tumors. In neither spleens nor lymphoid tumors was c-myc mRNA reduced (Figs. 4 and 5) . Perhaps a transcriptional feedback mechanism replenished c-myc mRNA presumably ablated by RNase H in the spleens of antisense treated animals. Such a feedback phenomenon has been observed in acute myelogenous leukemia cells treated with antisense DNA against p53, where the antigen level was also depressed, without concomitant reduction of the mRNA band on a Northern blot (43) .
In the micropump trial, anti-c-myc DNA therapy dramatically inhibited tumor progression when administered prophylactically, before the appearance of palpable tumors. The dose of racemic antisense DNA phosphorothioate administered corresponds to about 20 mg/kg/day over the 6 weeks of therapy. The rather high dose that allowed chemoprevention may in principle be reduced. Dose-response experiments which are underway should reveal how low a concentration will be effective. However, one may hypothesize that potency could be elevated significantly by use of stereospecific all-Rp phosphorothioate (44) or all-Rp methylphosphonate (45) oligomers, which display much stronger hybridization than the racemic oligomers used above. For prolonged or chronic therapy, intestinal uptake (46) might even allow oral administration.
The question of sequence specificity of antisense DNA inhibition must be addressed, particularly when the antisense sequence includes a G4 segment (47) . In the case of anti-c-myc DNA phosphodiesters used to inhibit proliferation of human promyelocytic HL-60 cells (7) (8) (9) (10) (11) (12) (13) (14) , 10 different sites from the 5' end to the beginning of the coding domain in the second exon of c-myc mRNA were targeted. All (Fig. 4) .
In view of the positive results of the micropump trial, one could postulate screening of individuals at risk for c-myc translocation, such as HIV-infected individuals. Although the 8:14 chromosomal translocation is not frequent enough in children to justify screening of a large population, it does occur frequently in HIV-infected individuals, inducing lymphomas (1). Acquired immunodeficiency syndrome (AIDS)-associated non-Hodgkin's lymphomas typically display translocation of c-myc to an immunoglobulin locus (51, 52) . If c-myc translocation precedes onset of lymphoma by any appreciable time, then screening might reveal positive evidence of c-myc activation prior to malignancy. Individuals displaying c-myc translocation could then be treated with antisense DNA to interdict tumor onset. It may therefore be reasonable to propose prophylactic anti-c-myc DNA therapy for HIVinfected individuals who display c-myc translocation in peripheral B cells. Would one not, however, expect to find systemic toxicity upon antisense inhibition of c-myc expression in proliferating cells? Fortunately for this prophylactic model, it has been observed in mice that DNA phosphorothioates are preferentially taken up by B cells, particularly when stimulated by a B cell mitogen (53) , which may now be said to include the 5'-dCACGTT segment of the anti-c-myc DNA itself (50) . Finally, the down-regulation of MYC protein observed in splenic lymphocytes (Fig. 3) suggests that anti-c-myc therapy might prove beneficial in those hematological malignancies in which cellular proliferation depends upon elevated c-myc expression.
Another significant question to be addressed concerns the extended tumor-free survival of 9 of the 12 antisense treated mice in the fourth trial (Fig. 2) . The original hypothesis predicted postponement of tumorigenesis during the course of antisense therapy (i.e., until the end of the sixth week of DNA administration, 9 weeks of age) but not long-term resistance. What mechanism could one then postulate to explain the phenomenon? In the case of E,u-myc mice, it may be that antisense inhibition of the expanded pre-B cell population limited the opportunities for establishment of tumor clones until the animals were sufficiently mature to eliminate transformed cells by normal immunological processes. In that case, 2 or 4 weeks of antisense therapy, up to an age of 7 weeks, might be insufficient to allow long-term resistance. Alternatively, up-regulation of c-myc expression at the end of therapy in transformed cells may have driven them into apoptosis, as with promyelocytic HL-60 cells (21) . It is also possible that antisense inhibition induced sufficient differentiation of cmyc transformed cells (11, 14) to expose them to immune surveillance and specific T cell activation. Bystander effects have been observed in other forms of genetic therapy (54,5 5) , including antisense therapy (56, 57) . It will be of great interest to examine and test the hypothetical forms of immunological activation set in motion by antisense DNA therapy.
